The LUNG-CARE project presented by Liang et al. aimed to evaluate the outcome of mass lung cancer screening in a Chinese general population and to investigate risk factors to improve risk assessment for screening.
The close association between air pollution and increased lung cancer risk has been known for decades, although causation remained unknown. Lung cancer in never smokers is characterized by a low mutational burden and the absence of a carcinogen-induced DNA mutation signature. In general, evidence against the classical mutation model explaining tumor growth as a result of DNA mutations has emerged, thus raising the need for an alternative model.
At least 40 % of patients with NSCLC have poor performance status (ECOG PS ≥ 2) and/or are elderly with multiple comorbidities and poor tolerance of treatment. They frequently receive single-agent chemotherapy or best supportive care as they are often deemed ineligible for first-line platinum-based regimens. Usually, they are excluded from clinical trials conducted in the first-line setting.
The first-in-class, oral, irreversible KRASG12C inhibitor sotorasib has given rise to durable clinical benefits in patients with advanced KRASG12C-mutated NSCLC in the phase II CodeBreak 100 trial, with an objective response rate (ORR) and median progression-free survival (PFS) of 37.1 % and 6.8 months, respectively.
The adjuvant use of the third-generation EGFR tyrosine kinase inhibitor (TKI) osimertinib is being explored in the phase III ADAURA study that includes almost 700 patients with completely resected stage IB, II, and IIIA, EGFR-mutant non-small-cell lung cancer (NSCLC), with or without adjuvant chemotherapy.
At the ESMO Congress held in Paris, France, and virtually from 9th to 13th September 2022, practice-changing data and high-quality education attracted more than 29,300 participants from over 150 countries.
